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Abstract
Background: Tuberculosis is the commonest opportunistic infection and the number one cause
of death in HIV/AIDS patients in developing countries. To address the extent of the tuberculosis
HIV coinfection in rural Tanzania we conducted a cross sectional study including HIV/AIDS patients
attending care and treatment clinic from September 2006 to March 2007.
Methods: Sputum samples were collected for microscopy, culture and drug susceptibility testing.
Chest X-ray was done for those patients who consented. Blood samples were collected for CD4+
T cells count.
Results: The prevalence of tuberculosis was 20/233 (8.5%). Twenty (8.5%) sputum samples were
culture positive. Eight of the culture positive samples (40%) were smear positive. Fifteen (75%) of
these patients neither had clinical symptoms nor chest X-ray findings suggestive of tuberculosis.
Nineteen isolates (95%) were susceptible to rifampicin, isoniazid, streptomycin and ethambutol
(the first line tuberculosis drugs). One isolate (5%) from HIV/tuberculosis coinfected patients was
resistant to isoniazid. No cases of multi- drug resistant tuberculosis were identified.
Conclusion: We found high prevalence of tuberculosis disease in this setting. Chest radiograph
suggestive of tuberculosis and clinical symptoms of fever and cough were uncommon findings in
HIV/tuberculosis coinfected patients. Tuberculosis can occur at any stage of CD4+T cells
depletion.
Background
Tuberculosis (TB) is the commonest opportunistic infec-
tion and the number one cause of death in HIV patients in
developing countries, and accounts for about 40% of all
manifestations seen in HIV patients [1]. About 25% to
65% of patients with HIV/AIDS have tuberculosis of any
organ and tuberculosis accounts for about 13% of all HIV
related deaths world wide [2-6]. While tuberculosis prev-
alence has declined by more than 20% worldwide, the
rates in Africa have tripled since 1990 in countries with
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high HIV prevalence and are still rising across the conti-
nent at 3–4% per year [7]. Between 1998 and 1999, a 20%
increase of tuberculosis cases was reported in countries
severely affected by HIV/AIDS in Africa[8]. Correct diag-
nosis and treatment of tuberculosis help to reduce the
burden of tuberculosis, provided that infectious cases are
detected and treated successfully. However, there are diffi-
culties in achieving the goal of reducing the tuberculosis
burden due to a number of challenges, such as difficulties
in diagnosing tuberculosis in HIV infected patients due to
unusual clinical picture with increase in smear negative
acid fast bacilli (AFB negative) pulmonary tuberculosis
disease, and atypical findings on chest radiography [9,10].
People with HIV are increasingly infected with tuberculo-
sis because HIV weakens their immune system[11] HIV/
AIDS fuels the tuberculosis epidemics in many ways, such
as promoting progression to active tuberculosis, increas-
ing the risk of reactivation of latent tuberculosis infection,
as well as increasing chance of tuberculosis infection once
exposed to tubercle bacilli [3,12]. Autopsy studies have
shown disseminated tuberculosis in 14–54% of HIV
infected people in HIV prevalent countries, many of
whom were undiagnosed prior to death [13]. The preva-
lence of tuberculosis in HIV patients on care and treat-
ment in rural Tanzania is not known. We report on the
prevalence of undiagnosed tuberculosis and drug suscep-
tibility among the HIV patients attending care and treat-
ment clinic in rural northern Tanzania.
Methods
Study design, setting and population
A cross sectional study was conducted at Haydom
Lutheran Hospital in northern rural Tanzania from Sep-
tember 2006 to March 2007. Haydom Hospital is a 400-
bed hospital in Mbulu District, owned by the Evangelical
Lutheran Church in Tanzania. The hospital serves a popu-
lation of about 250,000 from the surrounding three divi-
sions [14]. The hospital has facilities for tuberculosis and
HIV/AIDS diagnosis, treatment and monitoring
Study subjects
Subjects were recruited from the patients attending the
HIV care and treatment clinic. Eligible subjects were those
aged 10 years and above and who agreed to participate in
the study irrespective of their previous tuberculosis status.
Patients on tuberculosis treatment were excluded from the
study. Sputum was collected in a plastic leak-proof con-
tainer and sent to the Central Tuberculosis Reference Lab-
oratory (CTRL) for fluorescence microscopy, culture and
drug susceptibility testing. All patients were able to pro-
vide sputum samples, but for those who could not pro-
duce sputum spontaneously (43 patients); we used
induced sputum by inhalation of nebulised hypertonic
saline. The CTRL undergo proficiency testing and external
quality assessment by sending strains to a supranational
laboratory in Belgium for comparison of sensitivity test-
ing results. The time from sputum collection to the time
received at CTRL was 4 days. Blood was collected in ethyl-
ene diamine-tetra-acetic acid (EDTA) tubes. The same
sample was used for haemoglobin measurement and for
CD4+T cells count. Tuberculosis and HIV/AIDS diagnosis,
treatment and monitoring were given free of charge
according to Tanzanian national policy for tuberculosis
and HIV/AIDS management.
Laboratory procedure for tuberculosis diagnosis and 
Haematology
At the CTRL the sputum specimens were decontaminated
by using 2% sodium hydroxide (NaOH) and then concen-
trated by centrifugation at 3000 g. After centrifugation the
samples were examined by fluorescence microscopy and
also cultured on Lowenstein Jensen (LJ) medium and
incubated for 8 weeks. The smear microscopy, culture and
resistance test were done and interpreted according to the
National algorithm for mycobacterium smear microscopy
and culture[11]. CD4+T cells count were done using the
Becton Dickinson Fluorescent Activated Cell Sorter (BD
FACS Count, USA) haemoglobin measurement were done
using Sysmex Kx-21 (Sysmex Corporation; Kobe Japan).
Patients were interviewed, using a structured question-
naire. Physical examination, including anthropometric
measurements (height and weight), were recorded. Chest
radiography was done for all study subjects.
Ethical consideration
The protocol was approved by the Medical Research Coor-
dinating Committee of the Ministry of Health and Social
Welfare, Tanzania. Oral informed consent was obtained
from the patients prior to enrolment. For those below the
age of 18 years permission was sought from parents or
caretakers.
Data management and Statistical analysis
Completed questionnaires were coded by numbers and
double entered in a computer software Epi-data version
13.1. Cross-checking and data cleaning was done. The
data was then transferred to SPSS version 13 for analy-
sis[15] Categorical data were analysed by Chi square test.
The level of significance was set at p ≤ 0.05, and 95% con-
fidence interval was used throughout.
Definition of cases
Pulmonary tuberculosis was defined as cases positive for
acid fast bacilli by smear microscopy and/or culture.
Anaemia was classified as haemoglobin level < 10 g/dl
[16]. Immunological status was assessed by using CD4+ T
cells count, and patients with CD4 + T cells < 500 cells/
mm3 were classified as having immunosupression[17].
Nutritional status was assessed using body mass index
(BMI). Normal nutritional status was defined as BMI ofBMC Public Health 2008, 8:341 http://www.biomedcentral.com/1471-2458/8/341
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18.5–24.5 Kg/m2 and malnutrition as BMI < 18.4 Kg/m2
[18].
Results
Baseline characteristics of the study subjects
A total of 233 HIV/AIDS patients were included in the
study. The mean age of the study subjects were 37, SD
10.2. Twenty (8.6%) of all patients enrolled had tubercu-
losis, and thirty six (15.4%) of them had a history of
tuberculosis in the past 5 years. One (5%) of the tubercu-
losis/HIV coinfected patients and thirty five (16.4%) of
the HIV positive/tuberculosis negative patients had a his-
tory of previous tuberculosis within the past five years.
These patients with previous history of tuberculosis were
diagnosed to have HIV when they were attending the
tuberculosis clinic. One hundred and fifty (64.4%) were
on ARV while 83 (35.6%) were on regular follow up.
Patients on regular follow up are those who are not yet eli-
gible for antiretroviral drugs[19]. These patients usually
attend the clinic every four to six month for monitoring
the progression of the HIV infection.
Baseline characteristics of the study subjects are given in
table 1.
Chest radiograph, smear microscopy and culture
Smear microscopy and culture results for the study sub-
jects are given in figure 1.
Five (25%) of the HIV tuberculosis coinfected patients
had features suggestive of tuberculosis on chest radiogra-
phy; these 5 patients were also sputum smear microscopy
and culture positive for AFB.
Clinical symptoms of tuberculosis
Among patients with a diagnosis of tuberculosis by smear
microscopy
5 (62.5%) had fever for > 2 weeks, 2 (25%) had cough for
> 2 weeks and 4 (50%) were malnourished. All patients
with smear negative AFB microscopy and culture positive
AFB had no symptoms or chest radiography changes sug-
gestive of tuberculosis.
Smear microscopy and CD4+T cells count
One (12.5%) smear positive AFB patient had CD4+T cells
of < 200/mm3, 3 (37.5%) had a CD4+T cells of 200–349/
mm3 and 4 (50%) had CD4+T cells of > 350/mm3.
HIV tuberculosis coinfection and immunological status
Two thirds (3/20 (65%) of the HIV tuberculosis patients
had a CD4+T cells count of < 349 cells/mm3. Patients who
were HIV positive tuberculosis negative had higher CD4+
T cells count than the HIV tuberculosis coinfected
patients. The difference between mean CD4+ T cells
among people living with HIV/AIDS (PLWHA) infected
with tuberculosis and those PLWHA not infected with
tuberculosis is not statistically significant (p = 0.2). The
CD4+T cells for the study subjects are given in table 2
Table 1: Baseline characteristics of the study participants
Tuberculosis status
Characteristics Tuberculosis positive, N = 20 Tuberculosis negative, N = 213
N% n %
Age
12–24 2 10.0 14 6.6
25–34 9 45.0 75 35.5
35–44 6 30.0 79 37.1
45–54 2 10.0 31 14.7
> 55 1 5.0 14 6.6
Mean age (SD) 35.5 (9.5) 37.4 (10.4)
Sex
Male 6 30.0 52 24.4
Female 14 70.0 161 75.6
Marital status
Single 4 20.0 52 24.4
Married 10 50.0 102 47.9
Others* 6 30.0 59 27.7
Education
No education*** 6 30.0 81 38.0
Educated**** 14 70.0 132 62.0
* Includes separated, divorced, widowed and cohabiting.
*** Includes those did not go to school at all and those who dropped before finishing 7 years of primary education.
**** Those with primary education and above, there were only two who had education above primary school.BMC Public Health 2008, 8:341 http://www.biomedcentral.com/1471-2458/8/341
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Drug susceptibility testing
Drug susceptibility testing was done for the 20 culture
positive isolates. Nineteen (95%) were sensitive to
rifampicin, isoniazid, streptomycin and ethambutol. One
isolate (5%) was resistant to isoniazid, representing a
patient with a history of past tuberculosis treatment,
where isoniazid was one of the drugs used.
Antiretroviral treatment and tuberculosis
Ten (6.7%) HIV tuberculosis coinfected patients were on
ARV and 140 (93.3%) HIV infected tuberculosis negative
patients were on ARV. Thirty three (22%) of those patients
on ARV had a history of previous tuberculosis in the past
5 years, and 117 (78.0%) of the patients on ARV had no
history of previous tuberculosis. The mean duration for
ARV use in HIV tuberculosis coinfected patients was 6.8
Smear microscopy and culture results for the study subjects Figure 1










































Table 2: Immunological status of the study subjects
Tuberculosis status
CD4+T Cells count Tuberculosis positive N = 20 Tuberculosis negative N = 213
n % 95% CI n % 95% CI
< 200 Cells/mm3 6 30 9.9–50.1 72 33.8 27.5–40.2
200–349 Cells/mm3 7 35 14.1–55.9 48 22.5 16.9–28.1
350–500 Cells/mm3 4 20 2.5–37.5 36 16.9 11.9–21.9
> 500 Cells/mm3 3 15 -6.5–30.7 57 26.8 20.9–32.8
Mean CD4+T cells (SD) 277.9 (199) 181–368 355.0 (260) 320–390BMC Public Health 2008, 8:341 http://www.biomedcentral.com/1471-2458/8/341
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months S D 9.7 and for HIV infected tuberculosis negative
9.7 months S D 10.9.
Haemoglobin level
Five (15%) of the HIV tuberculosis coinfected patients
were anaemic and 15 (75%) had normal haemoglobin
level, while 52 (24.4%) of HIV infected tuberculosis neg-
ative were anaemic and 161 (75.6%) had normal haemo-
globin level.
Nutritional status assessment
Significantly more HIV tuberculosis coinfected patients
were malnourished (14/20, 70%, X2 = 7.2, p = 0.007) as
compared with HIV positive tuberculosis negative
patients 83/213 (39%). Six (30%) of the HIV/tuberculosis
coinfected patients had normal nutritional status and 130
(61%) of the HIV positive/tuberculosis negative patients
had normal nutritional status.
WHO Clinical staging of HIV/AIDS disease
WHO clinical stage for the study subjects is given in table
3
Using WHO clinical staging of HIV/AIDS disease we
observed 6 (30%) of HIV tuberculosis coinfected patients
in WHO stage III and 14 (70 %,) in stage IV.
Discussion
We found high prevalence of tuberculosis disease among
HIV/AIDS patients attending care and treatment in this
setting. A study done in Dar es Salaam found a prevalence
of 15% in patients attending HIV care and treatment
clinic[20]. Our prevalence of 8.5% is low when compared
with the study done in Dar es Salaam. The difference
between these two studies can be explained by the fact
that Dar es Salaam is urban and contributes about 24% of
all tuberculosis cases in Tanzania, while the rural area
where we did our study contributes less than 2%[11].
Patients with low immunity due to HIV are more likely to
acquire tuberculosis in an area with high tuberculosis
prevalence. Also, the prevalence of HIV in Dar es Salaam
is higher than the national average of 7%[21,22] and
higher than the prevalence of 2%[23] for the area where
we did our study. This means that there are relatively more
HIV patients who are susceptible to tuberculosis in Dar es
Salaam than in the area of our study. The prevalence of
8.5% is lower than 40–54% found in autopsy studies
done in HIV infected people who were undiagnosed prior
to death[13] However, these studies included all forms of
tuberculosis, while in our study we included pulmonary
tuberculosis only. In another study done in Fajara
Research clinic in Gambia among HIV patients who were
followed at the clinic, 43.2% were diagnosed to have
tuberculosis after 28 days of follow up, and 66% of them
had pulmonary tuberculosis confirmed by microscopy
and/or culture[24]. In yet another study done in South
Africa among African gold miners the point prevalence of
undiagnosed tuberculosis among HIV positive partici-
pants was 3.8% [25]. Our prevalence of 8.5% is close to
9% found in a study done in Cambodia [26]. Part of the
differences between the prevalence in our study and the
other studies may be due to differences in inclusion and
exclusion criteria. As patients already diagnosed to have
tuberculosis and started tuberculosis treatments were
excluded in our study, this may have given lower rates
than in some of the other studies.
Out of 20 tuberculosis patients in our study, smear was
positive in 8 (40%) patients, this is close to the figure of
42% reported in Ethiopia [27]. Most of the mycobacteria
isolated from these patients were susceptible to the first
line tuberculosis drugs (rifampicin, streptomycin, isoni-
azid and ethambutol). Resistance to isoniazid was found
in only one patient (5%), and no cases of multi-drug
resistant tuberculosis was identified; this is similar to the
report from the Tanzanian National tuberculosis control
program, where 90% of all isolates were sensitive to these
drugs and resistance to isoniazid was 5% [11]. However,
another study done in northern Tanzania showed that
among HIV tuberculosis coinfected patients resistance to
at least one drug was 10.8% [28]. A study done in Mwanza
Tanzania and published 10 years ago demonstrated that
among HIV tuberculosis coinfected patients 13% had
strains resistant to isoniazid, rifampicin, thiacetazone
and/or streptomycin[29] A recent study from Cambodia
shows that the resistance to anti tuberculosis drugs is
decreasing since the introduction of antiretroviral drugs
Table 3: WHO clinical stage for HIV/AIDS for the study participants
Tuberculosis status
WHO clinical stage Tuberculosis positive N = 20 Tuberculosis negative N = 213
n % 95% CI n % 95% CI
I 0 0 __ 23 10.8 6.6–14.9
II 0 0 __ 18 8.5 4.8–12.3
III 6 30.0 9.9–50.1 70 32.9 26.6–39.2
IV 14 70.0 9.5–90.1 102 47.9 41.2–54.6BMC Public Health 2008, 8:341 http://www.biomedcentral.com/1471-2458/8/341
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and there was a decrease of resistance from 48% in 1999
to 7.9% in 2004 [30].
Symptoms like fever, cough and weight loss were uncom-
mon among tuberculosis patients in this study. This unu-
sual presentation means that the screening of tuberculosis
among HIV patients by using symptoms of fever, cough,
weight loss and chest radiography with features suggestive
of tuberculosis would detect only 25% of the HIV tuber-
culosis infected patients. This suggests that chest radiogra-
phy and clinical symptoms, as recommended in Tanzania
for follow up screening of HIV patients for tuberculosis,
may not detect up to 75% of tuberculosis cases in people
living with HIV. Eight patients with tuberculosis were on
antiretroviral drugs for more than six months and yet
developed tuberculosis; this shows that there is a need to
do regular tuberculosis screening by sputum microscopy
and culture to diagnose tuberculosis in HIV patients on
treatment. Ten patients found to have tuberculosis were
not yet eligible for antiretroviral drugs. If tuberculosis
were diagnosed in these patients and correctly staged, they
would be eligible for antiretroviral drugs and cotrimoxa-
zole prophylaxis (CP) [11,19,31,32].
Anaemia was uncommon among the study subjects, 75%
of them had normal haemoglobin level. This could be due
to the regular check up of haemoglobin every time the
patients come to the care and treatment clinic, where
those who are found anaemic are treated free of charge.
Malnutrition was found in 70% of the coinfected patients.
Malnutrition and tuberculosis increases morbidity and
mortality in HIV patients [31,32]. Most of the HIV
patients, irrespective of their tuberculosis status, were in
WHO stage III and IV. This means that they present at hos-
pital in late stage with advanced disease. Overall, females
were more affected with HIV (71.1%) than males, may be
due to the fact that females are more vulnerable to HIV
than males because of their biological make up, and social
and cultural factors.
A strength of our study is that the data come from a clinic
that takes care of the HIV/AIDS patients daily, so our
results reflect the real situation in a rural HIV clinic,
though we have a small sample size. A limitation of our
study is that it is hospital based and the patients included
were those who were seriously ill. Thus, we might have
missed the group of not seriously ill patients who opted
not to attend the hospital for care. Also the culture media
Lowenstein Jensen we used lacks sensitivity; in this case
we might have missed some cases of tuberculosis. How-
ever in a resource poor setting countries like Tanzania the
only available culture media is Lowenstein-Jensen media,
therefore we used the available media to reflect the actual
situation in this poor setting
Conclusion
We found high prevalence of tuberculosis in this setting.
Chest radiographs suggestive of tuberculosis and clinical
symptoms like fever and cough were uncommon findings
in HIV tuberculosis coinfected patients. Tuberculosis can
occur at any stage of CD4+T cells depletion.
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